Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Bioactive coating to prevent catheter infection and thrombosis

Project description

Novel nanocoatings reduce common complications associated with catheterisation

Venous catheters are used ubiquitously to draw blood or deliver intravenous fluids, blood transfusions, chemotherapy, and other drugs. Insertion of a foreign object through tissue and into the bloodstream poses risks of clotting and infection. This can impact patient health and add an additional burden to healthcare systems. Functionalised nanogels are gaining tremendous interest for use in advanced surface coatings, drug delivery, diagnostics, and biomaterials. Now, researchers have exploited this potential in an advanced surface coating for catheters that will inhibit clogging, infection, and clotting. EU funding of the CMD-COAT project is supporting scientists in bringing their patented technology to market through the creation of a company, industrial partnerships, and a business plan that will attract funding.

Objective

Peripheral and central venous catheters are among the most implanted blood-contacting medical devices for short and long-term clinical applications, respectively. Despite implementations of in-hospital measures, catheters are often subject to infection and thrombotic complications, which result in longer hospitalization stay, higher health care costs, or even death. The CMD-COAT project aims at providing an innovative and rapid solution to this major medical, economical and societal need. The solution comes from our patented technology, referred to as Coatigel, that consists of grafting multilayer cross-linked nanogels with combined antifouling, antimicrobial and antithrombotic properties onto catheter surface. The combination of these properties can guarantee longer catheter clinical performance than any currently available products. Our project includes all the validation steps that will enable us to bring Coatigel on the catheter market. We will assess Coatigel compliance with ISO standards and compile the technical file for CE mark application in accordance with EU directives for class III medical devices. The whole process will be realized under the guidance of a company specialized in quality management to ensure optimal reliability and efficacy. The project also involves setting up partnerships with catheter industries to adjust our technology to manufacturing constraints. Via services of marketing experts, we will take on a competitive market analysis, including geographic segmentation, to position Coatigel in the catheter market. This project will result in the creation of a coating spin-off company with the exclusive right of Coatigel commercial exploitation. The presence of several big catheter manufacturers in Belgium is a main asset for our business success. All this will be achieved thanks to the help of local support in intellectual property management, consolidating industrial partnerships, and in contacts with potential investors.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2019-PoC

See all projects funded under this call

Host institution

UNIVERSITE DE LIEGE
Net EU contribution
€ 150 000,00
Address
PLACE DU 20 AOUT 7
4000 LIEGE
Belgium
Region
Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)